Method for treating mammary gland cancer

FIELD: medicine, oncology.

SUBSTANCE: during the first day of therapy it is necessary to affect the lesion focus with alternating magnetic field at induction being 5-160 mTl, frequency of 50-100 Hz for about 7-10 min. Out of peripheral vein one should sample blood into two vials with hemoconservant per 100 ml/each; one vial should be supplemented with doxorubicin at the dosage of 50 mg/sq. m, the second vial - with 5-fluorouracil 750 mg/sq. m. Both vials should be incubated. Then it is necessary to inject intravenously by drops the content of the first, and then of the second vial for a patient. During the period since the first day up to the seventh one it is necessary to introduce cyclophosphan intramuscularly per 200 mg/sq. m. Since the first up to the tenth day of therapy one should affect with alternating and direct magnetic field. On the eighth day after seances of magnetic therapy one should repeatedly introduce anti-tumor chemopreparations at the same dosages and sequence. In two weeks it is necessary to repeat the above-mentioned curative impacts. In two weeks after the last introduction of chemopreparations one should fulfill surgical removal of lesion focus. The innovation enables to avoid side toxic manifestations of chemopreparations and notching of sutures and, also, healing due to secondary tension.

EFFECT: higher efficiency of therapy.

1 ex

 

The invention relates to medicine, more specifically to Oncology, and can be used in the treatment of patients with edematous-infiltrative form of breast cancer.

There is a method of treating breast cancer with spread to the surrounding tissue, inflammation and oedema of the surrounding tissues and metastasis to the parasternal lymph nodes, when is radical mastectomy extended scale (holding S.A., dymarski LU "Extended radical surgery for breast cancer", HP, "Medicine", 1975).

However, the authors questioned the desirability and feasibility of an online radical interventions, an obstacle which is not only extensive area of damage and the need to eliminate the defect of the skin, but also the presence of the inflammatory process.

There is a method of treatment for breast cancer, when the first stage is realized by the introduction of anticancer chemotherapy. After three weeks, a second course of chemotherapy, and then on the mammary gland and area regional metastasis perform radiation therapy split rate for three-four weeks and repeat chemotherapy. (Tailor S.M., Ptuskin CENTURIES, Timescan K.L. and others ' Experience of treating patients prognostically burdened locally common cancer of the mammary glands is". M, 2003)

The proposed method of treatment involves the impact not only on the lesion, but also on the regional metastasis sites. However, the duration of its execution, adverse toxic manifestations as chemotherapy and radiotherapy negatively affect the condition of patients. The use of such dataintensive regimes of chemotherapy entails an increase in the number and severity of side effects of drugs, increased gastrointestinal syndrome, the development of immunosuppression suppression division and growth of blood stem cells, until the development of pancytopenia.

The aim of the invention is the possibility of surgical removal of the lesion.

The goal is achieve by exposure to the lesion alternating magnetic field induction 5-160 MT and a frequency of 50-100 Hz for 7-10 minutes, then a uniform magnetic eld of 200 MT induction. Then make a fence of a blood from a peripheral vein in two vial geoconservation 100 ml each; in one vial, add doxorubicin at a dose of 50 mg/m2in the second 5-fluorouracil based 750 mg/m2both bottles incubated in thermostat and injected intravenously content first, and then a second bottle on the first day of treatment. From the first to the seventh day of treatment injected intramuscularly with 200 mg/m2of cyclophosphamide. the effects of variable and constant magnetic field is carried out from the first to the tenth day of treatment, and on the eighth day after session magnet therapy is re-administered anticancer drugs in the same doses and sequence. Then two weeks later, repeat the above treatment and two weeks after the last drug administration perform surgical removal of the lesion.

The use of magnetic influence of different nature as a therapeutic component or to increase the resistance was proven by the works of the staff of the Institute in experiment and clinic. (Salads R.N. Magnetotherapy in the treatment of inflammatory processes and malignant neoplasms: author. of thesis ... Dr. med. Sciences. Rostov n/a, 2001)

This was the basis for developing a method for the treatment of edematous-infiltrative form of breast cancer. Known methods of treatment did not bring significant results were very time of their execution, and it lay on the condition of patients and very significantly influenced by the lesion.

Analysis of the known methods of treatment for breast cancer edematous-infiltrative form and developed allows us to state its novelty and significant differences.

The novelty of the proposed "cure breast cancer" is simultaneously local and General effects on the organism as a follower of the spine of the application of the magnetic field and anticancer chemotherapy.

In open sources information of Russia, CIS and abroad similar to the claimed method was not found.

"A method for the treatment of breast cancer" is industrially applicable, it can be reproduced and repeated many times in the institutions as specialized and General health profile, it is possible to use both in hospitals and in clinics.

The method is as follows.

After cytological verification of diagnosis patients realize the effects of alternating magnetic field induction 5-160 MT and a frequency of 50-100 Hz, lasting 7-10 minutes, then the static magnetic field induction 200 MT for 7-10 minutes, then from a peripheral vein produce fence autologous blood in two vial geoconservation 100 ml in each. In the first vial add doxorubicin at a dose of 50 mg/m2pre-dissolved in physiological solution; in the second vial is administered 5-fluorouracil based 750 mg/m2after which both of the vial is incubated in thermostat and intravenously injected the contents of the first and then second bottles on the first day of treatment. Additionally, from the first to the seventh day of treatment the patient is administered intramuscularly in a dose of 200 mg/m2of cyclophosphamide. The impact of variable and constant magnetic field is performed with the first on desethylene treatment in the same modes and sequences. On the eighth day of treatment after sessions of exposure magnets re-inject these drugs, United with Autocraft, in the same doses and order. Two weeks later, repeat the same course of treatment, and then two weeks after the last drug administration perform surgery in the amount of radical mastectomy.

A specific example of the method can serve as a statement of history.

Patient N. in 1957, the case history No. 2748/f, received 16 February 2005 in the Department of breast tumors, soft tissue and bone Rostov cancer research Institute with complaints about the presence of swelling and slight hyperemia of the skin of the left breast.

Sick right physique, satisfactory nutritional status. Skin and visible mucous regular color. Musculoskeletal system without visible signs of pathology. The turgor of tissues is saved. The boundaries of the lung in normal limits. Percutere clear pulmonary sound, vesicular breathing, wheezing no. Pulse uniform, satisfactory filling and voltage. Heart sounds are clear, rhythmic. HR 60 minutes HELL 110/70 mm Hg Language damp, not lined. The abdomen is soft, palpation painless in all departments. The liver is not enlarged. Symptom tapping negative obey the sides. Physiological functions: the tendency to constipation. Veins of the lower extremities slightly extended. Comorbidities: chronic cholecystitis, cervical erosion.

The breast is developed correctly. In the right breast nodules were not found. The left breast is a little bigger in size compared to the right, a slight redness of the skin glands, swelling (a symptom of "lemon peel"), retracted nipple, not shown, areola tight, swollen, upper-inner quadrant of fuzzy dense substrate to 1.5×2 cm on the background of fibrosis. In the left axillary region lymph node up to 1 cm, densely-elastic, relatively movable.

The patient was performed by needle biopsy (cytological analysis No. 3581-85), found in the breast and axillary lymph node layers of cells ductal cancer.

on 18 February 2005, we launched the course of magnetic therapy to the lesion alternating magnetic field induction 100 MT and a frequency of 50-100 Hz, for 7 minutes, then a uniform magnetic eld of 200 MT induction. Then made a fence of a blood from a peripheral vein in two vial geoconservation 100 ml each; in one vial was added doxorubicin at a dose of 50 mg/m2in the second 5-fluorouracil based 750 mg/m2both bottles were incubated in thermostat iwali intravenous drip the contents of the first, and then the second bottle. The introduction was made on the first day of treatment. From the first to the seventh day of treatment was administered intramuscularly in a dose of 200 mg/m2of cyclophosphamide. The impact of variable and constant magnetic field was carried out from the first to the tenth day of treatment, and on the eighth day after sessions of magnetic therapy re-introduced anti-tumor drugs in the same doses and sequence.

After the first treatment there was a slight decrease in the redness of the skin of the left breast. In the inner quadrants remained swelling of the left breast. The nipple was slightly involved were not shown, areola became a little softer. In the upper inner quadrant of the substrate is practically not been determined. In the left axillary region remained lymph node up to 1 cm, densely-elastic, relatively movable.

Two weeks after the last drug administration March 17, 2005 the patient was started a second course of magnetic therapy to the lesion alternating magnetic field induction 100 MT and a frequency of 50-100 Hz, for 7 minutes, then a uniform magnetic eld of 200 MT induction. Then made a fence of a blood from a peripheral vein in two vial geoconservation 100 ml each; in one vial was added doxorubicin at a dose of 50 mg/m2in the second 5-fluorouracil based 750 mg/m2both fluorescence is Kona incubated in thermostat and injected intravenously contents of the first, and then the second bottle. The introduction was made on the first day of treatment. From the first to the seventh day of treatment was administered intramuscularly in a dose of 200 mg/m2of cyclophosphamide. The impact of variable and constant magnetic field was carried out from the first to the tenth day of treatment, and on the eighth day after sessions of magnetic therapy re-introduced anti-tumor drugs in the same doses and sequence.

After the second course of treatment was mentioned by almost complete disappearance of the redness of the skin of the left breast. In the inner quadrants remained a slight swelling of the left breast. The nipple was released, areola became softer. In the upper inner quadrant of the substrate is practically not been determined. In the left axillary region lymph node decreased to 0.5 see Adverse reactions of chemotherapy were observed. Indicators of blood leukocytes ranged within normal limits (from 4.4 to 6.7×10 / l).

Then two weeks after the last drug administration April 12, 2005 patient N. was performed a radical mastectomy on the left. The results of histopathological studies No. 795643-649 - infiltrating ductal cancer with a pronounced intraductal component, with a diffuse infiltrative growth; degenerative changes of tumor cells; mts 2 subclavian and 2 axillary lymphatics is their nodes. Complications after surgery was not. The patient was discharged on April 27, 2005 in a satisfactory condition. Is medical supervision.

June 22, 2005 at the next examination the patient is in satisfactory condition. No complains. The left hand operates in full. Lymphostasis of the upper limb is observed.

The proposed method was implemented treatment 15 patients edematous-infiltrative form of breast cancer. Neither one patient was noted to have adverse toxic effects of chemotherapy. The treatment was carried out in full. All patients were operated up to the present time are in a satisfactory condition, 80% of them returned to work.

Technical and economic efficiency of the method:

- to avoid adverse toxic effects of chemotherapy;

- to reduce the preoperative stage of treatment;

to improve the results of the postoperative period, avoiding the eruption of the joints and healing by second intention;

- to improve the quality of life of patients with edematous-infiltrative form of breast cancer.

A method of treating breast cancer, including the effects of variable and constant magnetic fields and the introduction of anticancer chemotherapy, United with Autocraft Inc. and irovannyh in thermostat, characterized in that on the first day of treatment exercise effects on lesion alternating magnetic field induction 5-160 MT and a frequency of 50-100 Hz for 7-10 minutes, then a uniform magnetic eld of 200 MT induction 7-10 minutes, then from a peripheral vein produce blood sampling in two vial geoconservation 100 ml each, in one vial, add doxorubicin at a dose of 50 mg/m2in the second 5-fluorouracil 750 mg/m2both bottles are subjected to incubation, and then intravenously injected the contents of the first patient, then the second vials, from the first to the seventh day intramuscularly injected with 200 mg/m2of cyclophosphamide, the effects of variable and constant magnetic field is carried out from the first to the tenth day of treatment, on the eighth day after session magnet therapy is re-administered anticancer drugs in the same doses and sequence, then two weeks later, repeat the above treatment and two weeks after the last drug administration perform surgical removal of the lesion.



 

Same patents:

FIELD: pharmaceutical industry, in particular agent having cytostatic and apoptosis-inducing activity.

SUBSTANCE: claimed agent represents β-Asparagine, obtained by extraction of ground burdock roots having specific particle size with heated water in specific raw materials/extractant ratio; decoction, extract separation, concentration up to dry residue in concentrate, filtering, and double recrystallization.

EFFECT: agent with high cytostatic and apoptosis-inducing (anti-tumor) activity.

5 dwg, 2 tbl

FIELD: medicine, oncology.

SUBSTANCE: method involves carrying out lumbal puncture to a patient in post-operative period, subarachnoid space is catheterized, and 5 ml of liquor is removed followed by incubation of liquor with nimustine taken in the dose 5 mg in vitro at temperature 38°C for 30 min, and liquor is administrated into subarachnoid space through catheter. Procedure is carried out 2 times with interval for 7 days. Since the second day after onset of this procedure distant gamma-therapy on bed of removed tumor is carried out up to the total focus dose 60 Gr. Method provides stable remission, decreasing toxicity of chemopreparation, frequency of adverse by-side effects and significant reducing the cost of chemotherapy. Invention can be used in carrying out the adjuvant chemoradiation therapy of brain malignant glial tumors.

EFFECT: improved method of chemoradiation therapy, enhanced effectiveness of method.

1 ex

FIELD: medicine, oncology, gynecology.

SUBSTANCE: method involves trepanopuncture of flank bone wing, aspiration of bone marrow suspension in the amount 150-200 ml followed by incubation of suspension with chemopreparations cisplatin and cyclophosphan at temperature 37°C for 40 min in doses above therapeutic ones. Doxorubicin is not incubated with bone marrow suspension and chemopreparations are administrated separately by intravenous route, by drops in indicated order in day when the bone marrow suspension has been taken, and this procedure is repeated with interval for 3-4 weeks but totally 4 times per one treatment course. Proposed method provides attaining the stable anti-tumor effect up to the complete tumor regression in this category of patients showing high tolerance to chemotherapy, and in practical absence of adverse toxic responses. Invention can be used in treatment of patients with relapses of ovary and uterus body cancer in case absence effectiveness of other methods of treatment or in case of their low effectiveness.

EFFECT: improved method of treatment.

2 ex

FIELD: medicine, oncology.

SUBSTANCE: method involves administration of bleomycin and erythropoietin simultaneously in patients. Invention can be used for decreasing pulmonary cytotoxicity in patients treated with bleomycin. Invention provides improving functioning lung in patients of this category.

EFFECT: valuable medicinal properties of erythropoietin.

4 cl, 2 dwg, 2 ex

FIELD: medicine, oncology, pharmacology, pharmacy.

SUBSTANCE: invention relates to methods and medicinal formulations used in antitumor treatment and enhancing oral biological availability of taxanes. Method involves administration of taxane in combination with agent enhancing biological availability of taxane in oral administration in subject wherein concentrations of taxane attain levels of therapeutic activity in subject. Ketoconazol representing inhibitor of cytochrome P-450 is used as agent enhancing oral biological availability of taxane. Invention provides enhancing bioavailability of taxane in its oral administration in subject in subtherapeutic doses that results to decreasing toxicity of treatment.

EFFECT: improved and valuable medicinal properties of drug.

33 cl, 42 dwg, 10 tbl, 12 ex

FIELD: chemistry, medicine.

SUBSTANCE: invention relates to hemin-peptide of general formula I , wherein R1 is ArgTrpHisArgLeuLysGlu(OMe)OH; R2 is -OH; Y is Cl; Me is Fe, or pharmaceutically acceptable salts thereof having virulicidal and anti-viral activity, including activity against herpes virus and HIV, and capability for destroying of λ fag, herpes and HIV DNA. Hemin-peptide fragment also is disclosed.

EFFECT: new anti-viral agent.

2 cl, 5 tbl, 5 ex

FIELD: organic chemistry, biochemistry, medicine.

SUBSTANCE: invention relates to derivatives of 2-aminonicotine amide of the formula (I): , to methods of their synthesis and a pharmaceutical composition based on thereof inhibiting activity of receptor tyrosine kinase vessel endothelial growth factor (VEGF) and to corresponding method for inhibition of activity of VEGF-receptor tyrosine kinase. It is suggested that this activity will allow offering the curative effect in proliferative diseases associated with angiogenesis, in particular, in treatment of tumors, retinopathy or age degeneration of yellow (corneal) spot.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

9 cl, 42 ex

FIELD: medicine, ophthalmology, ophthalmooncology.

SUBSTANCE: one should intravenously inject a photosensitizer photosens at 0.1-1.0 mg/kg patient's body weight. In about 48-72 h since the moment of photosens injection it is important to detect the presence of preparation's therapeutic dosage in the tumor. For this purpose one should specify the coefficient of contrast degree between the tumor and healthy adjacent tissues. Planning of photodynamic therapy should be fulfilled individually by orienting to concrete values of the coefficient of contrast degree in a concrete patient. At the value of coefficient of contrast degree being ≥4, but under 10 it is necessary to irradiate with low single dosages (ranged 80-150 mW/sq. cm) by increasing the number of seances conducted (up to 10). At the value of the above-mentioned coefficient being ≥10.0 irradiation should be carried out once or during 2-3 seances at high single radiation dosages (ranged 150-800 mW/sq. cm). The innovation enables to optimize therapy in patients with intraocular tumors.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: organic chemistry, medicine, oncology.

SUBSTANCE: invention relates to using dicarboxylic acids of the general formula (2): R-CONH-OH (2) wherein R means -HO-HNCO, -HO-NHCOCH-(OH)CH(OH), -HOOC-CH2CH2, -HO-OCCH=CH as inhibitors of metastasis and agents enhancing chemotherapeutic activity of antitumor preparations. Also, invention relates to a method for enhancing effectiveness of cytostatics in carrying out cytostatic chemotherapy of tumors. Method is carried out by using cytostatics in combination with derivatives of dicarboxylic acids of the formula (2). Also, invention relates to a method for inhibition of metastasizing process. Method is carried out by effect of the known cytostatics and derivatives of dicarboxylic acid of the formula (2) on tumor. Proposed substances provide enhancing antitumor and anti-metastatic activity of known cytostatics based on using derivatives of dicarboxylic acids.

EFFECT: valuable medicinal properties of agents and preparations, enhanced effectiveness of metastasizing inhibition.

4 cl, 4 dwg, 7 ex

FIELD: medicine.

SUBSTANCE: method involves impregnating sterile gauze napkins with Tactivin solution, in the amount of 100 mcg per each napkin, and imposing it on mammary gland. Then, variable magnetic field treatment is applied. When applying the procedure one day and one hour prior to operation the napkins are arranged on both sides with respect to nodular formation, 3 cm far from it. When carrying out the procedure at the third day after operation, napkins are placed directly onto zone under operation.

EFFECT: reduced risk of complications in postoperative period.

FIELD: medical engineering.

SUBSTANCE: device has head with a bundle of needles attached to the casing and detachable from it and handle manufactured from springy material having end gripe. The head member is manufactured from non-magnetic material. Permanent magnet is available in the casing. The magnetic axis is directed in perpendicular to needle axes manufactured from ferromagnetic material and arranged in two equal groups near permanent magnet poles.

EFFECT: enhanced effectiveness of treatment; increased reflexogenic zone irritation.

1 dwg

FIELD: medicine; cardiology.

SUBSTANCE: method includes magnetic-laser influence of pulse laser radiation onto cubitus. Course of treatment includes 10 procedures with duration of 7 minutes each. First 5 procedures are taken daily and the rest ones - every other day. Laser radiation power density equals to 8,93 mW/mm2, magnetic induction is 50 microtesla. From the first day of treatment, the respiratory gymnastics should be done to work out diaphragm breathing by training. For the purpose, patient moves actively with his/her front abdominal wall when breathing through nose in and when breathing out he/she pulls belly inside through close lips. Breathing frequency equals 3-5-7 times a minute, duration of procedure equals to 13-20 minutes.

EFFECT: improved of adaptive abilities of human body; normalized lipidic exchange; prolonged period of remission.

2 ex, 9 tbl

FIELD: medicine, urology.

SUBSTANCE: one should affect with light-diode radiation, magnetic field rectally onto prostatic projection, carry out micro-enemas of magnetized mineral water, magnetotherapy onto areas of pubis, sacrum and perineum. In case of chronic prostatitis in case of exacerbation one should affect with blue, infrared radiation and magnetic field. In case of chronic prostatitis at the stage of remission - with blue, infrared radiation and magnetic field during the first 3-4 procedures, and then - with red, infrared radiation and magnetic field during the next 5-8 procedures, daily, about 8-12 procedures/course. The method enables to carry out differentiated treatment of chronic prostatitis depending upon the activity of inflammatory process and decrease manifestation of pathological side reactions.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: method involves rectally exposing prostate projection zone to red, infrared radiation, magnetic field and magnetic therapy is applied to sacral region, pubis and perineum. Magnetized sapropelic tampon is introduced into the rectum after applying combined rectal treatment. Tampon volume is equal to 140-160 ml and hold for 30-40 min under temperature of 37-38°C and magnetic therapy is applied to sacral region, pubis and perineum region.

EFFECT: wide range of therapeutic applications.

Medical applicator // 2269368

FIELD: medical engineering.

SUBSTANCE: device has metal casing having permanent magnet inside. Electrode is outside of the casing and connected to electric current source. The second electrode, manufactured from non-magnetic material having cavity, is inside of the casing. Permanent magnetic is mounted in the cavity. Substance like mineral solution or plant oil is placed between the electrodes. Dielectric bushing is mounted in the casing for insulating electrodes and substance from the casing. Electric current supply source is mounted with one of its contacts on the first electrode and with its second electrode having ironwork fault. One of applicator embodiments has spring placed between electric current supply source and casing. Another version has electrode mounted outside of the casing. It is manufactured from nonferrous metal having silver coating.

EFFECT: wide range of functional applications.

3 cl, 1 dwg

FIELD: medicine, surgery.

SUBSTANCE: the present innovation deals with operative interference followed by the impact with magnetolaser infrared radiation of 80 Hz frequency per 30 sec or 2-4 fields and with direct magnetic field at the value of magnetic induction being 25-50 mTl for 10-20 min successively. At first, one should affect postoperational area, the - reflexogenic area at one's foot, daily for 8-12 d. Since the 9th - 13th d one should affect with single direct magnetic field with the value of magnetic induction being 25-50 mTl for 10-20 min successively. At first, one should affect postoperational area, then - reflexogenic area at one's foot for 10 -12 d. The innovation decreases the frequency of postoperational complications.

EFFECT: shortened terms of therapy.

2 ex

FIELD: medical engineering.

SUBSTANCE: method involves acting in turn with ultrasonic and magnetic field with switch frequency of 10 to 160 Hz. Ultrasonic field intensity is set below cavitation threshold and ultrasonic oscillation frequency being equal to liquid acoustic relaxation frequency. Magnetic field induction being selected within the limits of 30-50 mTesla units.

EFFECT: enhanced effectiveness of liquid activation; reduced power consumption.

1 dwg

FIELD: medicine.

SUBSTANCE: method involves carrying out vitrectomy with posterior hyaline membrane being removed. Retinotomy is carried out with subretinal neovascular complex being removed. Autogenous pigment retinal epithelium is subretinally introduced through retinotomy area as stratum or suspension. The intravitreous tamponade is carried out with perfluororganic compound substituted with air next to it. Flexible polymer magnetolaser implant having ring-shaped magnet with axial permanent magnetic field magnetization of 3-7 mTesla units is extrasclerally mounted into tunnel built between sclera and Tenon's capsule in macular area projection zone. The implant is turned with S pole towards transplanted cells so that laser radiation-emitting lens is arranged in their projection zone. Implant light guide is sutured to sclera 5-6 mm far from limb. The implant is covered with conjunctiva. Light guide outlet is attached to temple. The introduced cells are treated via laser light guide and implant lens with divergent continuous laser radiation. The magnetic implant is removed after having finished the treatment course and sutures are placed on conjunctiva.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine.

SUBSTANCE: method involves carrying out transpupillary laser coagulation of central avascular zones and transscleral cryocoagulation of peripheral avascular retina zones. 3-4 mm long incisions in conjunctiva and Tenon's capsule are done between sclera and Tenon's capsule in perpendicular to limbus 3-4 mm far from it. Tunnel is built in projection zone of an avascular retina zone between sclera and Tenon's capsule in parallel to the limbus on both sides of the incision. Flexible polymer magnetic implant is extrasclerally introduced into the tunnel in projection zone of an avascular retina zone. The implant has its own permanent magnetic field with magnetic poles alternating on each of sides and permanent magnetic field intensity of 0.5-1.0 mTesla units. The implant is sutured with one of its ends to sclera, and suture is placed on conjunctiva, and anti-oxidant therapy is applied. Magnetic stimulation therapy course is applied 3-4 weeks later. The course combines actions of permanent magnetic field produced by extrasclerally arranged magnetic implant and external rotating permanent magnetic field of 0.30-0.40 mTesla units intensity. Periodicity of external magnetic field action is selected to be 1-2 times per day with external action duration being equal to 3-5 min per 1 session during 10 days. The extrasclerally arranged flexible polymer magnetic implant is removed when treatment course is over. The flexible polymer magnetic implant is manufactured from biologically stable polymer material like one on polypropylene, polyester or polyethylene basis having permanent magnet material powder particles uniformly distributed therein. Magnetic material particles are of samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen base.

EFFECT: enhanced effectiveness of prophylactic treatment; prevented severe disease forms progress; released retina edema.

6 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out transpupillary laser avascular zones coagulation. Taurin is dropped into conjunctival cavity at a dose of 1-2 drops into the eye under treatment 5-6 times a day during 7-10 days. 0.02% Histochrome solution is dropped into conjunctival cavity at a dose of 2 drops into the eye under treatment 5-6 times a day during 7-10 days. 0.02% Histochrome solution or 0.02% Emoxipin solution or 1% Retinalamine solution in the amount of 0.4-0.6 ml once a day is parabulbary introduced as antioxidant during 7-10 days. Magnetic stimulation course is applied on the background of conservative therapy to orbital or temporal head region of prematurely born child in any succession using external rotating permanent magnetic field of 0.15-0.40 mTesla units intensity. Periodicity of external magnetic field action is selected to be 1-2 times per day with external action duration being equal to 3-5 min per 1 session during 10 days with magnetic field being 15-30 cm far from orbital or temporal head region of prematurely born child. External permanent magnetic field rotating at constant or variable speed is applied for carrying out magnetic stimulation treatment. Repeated conservative therapy and magnetic stimulation treatment with external rotating permanent magnetic field is additionally applied in 1-3 months. The number of repeated courses is equal to 1-3.

EFFECT: enhanced effectiveness of prophylactic treatment; prevented severe disease forms progress; released retina edema; improved blood circulation in avascular zones.

3 cl

FIELD: medicine, surgery.

SUBSTANCE: the present innovation deals with preventing purulent-septic complications in early post-surgical period at surgical treatment of gangrene-complicated ischemic foot form. During 3-5 d before operation and during 7-8 d after it one should introduce perorally ADP-37 preparations for patients at the dosage of 6 capsules daily followed by intramuscular injection of mexidol immediately after operation at the dosage of 2.1 mg/kg body weight, and during the next 3 d - at the same dosage every 12 h. Surgical wound should be treated with a gel that contains 2%-mexidol followed by affecting the wound with impulse magnetic field at 0.5-1.0 Tl intensity.

EFFECT: the innovation enables to prevent the development of purulent complications, stimulate reparative process, reconstruct the structure and the functioning of microcirculatory system in limb's soft tissues.

2 ex

Up!